PMID- 24683204
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140331
LR  - 20211021
IS  - 0011-393X (Print)
IS  - 0011-393X (Linking)
VI  - 68
IP  - 3
DP  - 2007 May
TI  - Criteria for choosing clinically effective glaucoma treatment: A discussion panel 
      consensus.
PG  - 127-36
LID - 10.1016/j.curtheres.2007.06.002 [doi]
AB  - Abstract. BACKGROUND: In the clinical management of patients at risk for or 
      diagnosed with primary open-angle glaucoma (POAG), the aim of medical treatment 
      is to reduce intraocular pressure (IOP) and then maintain it over time at a level 
      that preserves both the structure and function of the optic nerve. OBJECTIVE: The 
      objective of this report was to establish a consensus on the criteria that should 
      be used to determine the characteristics of IOP-lowering medication. METHODS: 
      Discussion was held among a panel of 12 physicians considered to be experts in 
      glaucoma to develop a consensus on the criteria used by them to determine the 
      characteristics of the IOP-lowering medication chosen for initial monotherapy and 
      adjunctive treatment of ocular hypertension (OHT) or POAG. Consensus development 
      combined available evidence and the impressions of these physicians regarding the 
      clinical effectiveness of IOP-lowering medication for OHT and POAG. Once the 
      panel identified the criteria, the order of priority and the relative importance 
      of these criteria were then established in the setting of 3 risk categories (low, 
      medium, and high) for a patient to experience significant visual disability from 
      glaucoma over their expected life span. RESULTS: The panel identified 5 criteria 
      to determine the characteristics of IOP-lowering medication for OHT and POAG: 
      IOP-lowering effect, systemic adverse events (AEs), ocular tolerability, 
      compliance/administration, and cost of treatment. IOP-lowering effect was 
      consistently ranked as the highest priority and cost as the lowest. The priority 
      of compliance/administration did not vary by clinical situation. Systemic AEs and 
      ocular tolerability were ranked as higher priorities in initial monotherapy than 
      in adjunctive treatment and ranked lower as the risk for visual disability 
      increased. The priority given to the criteria used to determine clinical 
      effectiveness varied both with the risk for functional vision loss from glaucoma 
      and whether initial monotherapy or adjunctive treatment was being considered. 
      CONCLUSION: Glaucoma treatment should be assessed with regard to the need not 
      only to lower IOP but also to minimize systemic and ocular AEs, promote patient 
      compliance, and minimize cost. The order of priority and relative importance 
      given to these treatment criteria will vary as part of individualizing patient 
      care.
FAU - Thygesen, John
AU  - Thygesen J
AD  - Department of Ophthalmology, Rigshospitalet, University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Burk, Reinhard
AU  - Burk R
AD  - Department of Ophthalmology, Academic Hospital Bielefeld, Bielefeld, Germany.
FAU - Carassa, Roberto
AU  - Carassa R
AD  - Department of Ophthalmology and Visual Sciences, San Raffaele Hospital, Milan, 
      Italy.
FAU - Crichton, Andrew
AU  - Crichton A
AD  - Department of Surgery, University of Calgary, Calgary, Alberta, Canada.
FAU - Goni, Francisco Javier
AU  - Goni FJ
AD  - Institut de Microcirurgia Ocular (IMO), Universidad Autonoma de Barcelona, 
      Barcelona, Spain.
FAU - Menage, Mitch
AU  - Menage M
AD  - Leeds General Infirmary, Leeds, United Kingdom.
FAU - Miglior, Stefano
AU  - Miglior S
AD  - University of Milan Bicocca, Milan, Italy.
FAU - Montgomery, Donald
AU  - Montgomery D
AD  - Eye Department, Glasgow Royal Infirmary, Glasgow, United Kingdom.
FAU - Nordmann, John-Philippe
AU  - Nordmann JP
AD  - Centre Hospitalier des Quinze-Vingts, Paris, France.
FAU - Roberts, Tim
AU  - Roberts T
AD  - Department of Ophthalmology, Royal North Shore Hospital, University of Sydney, 
      Sydney, Australia.
FAU - Singh, Kuldev
AU  - Singh K
AD  - Department of Ophthalmology, Stanford University Medical Center, Stanford, 
      California, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Ther Res Clin Exp
JT  - Current therapeutic research, clinical and experimental
JID - 0372621
PMC - PMC3967348
OTO - NOTNLM
OT  - consensus
OT  - criteria
OT  - glaucoma
OT  - intraocular pressure
EDAT- 2007/05/01 00:00
MHDA- 2007/05/01 00:01
PMCR- 2007/05/01
CRDT- 2014/04/01 06:00
PHST- 2007/04/26 00:00 [accepted]
PHST- 2014/04/01 06:00 [entrez]
PHST- 2007/05/01 00:00 [pubmed]
PHST- 2007/05/01 00:01 [medline]
PHST- 2007/05/01 00:00 [pmc-release]
AID - S0011-393X(07)00049-5 [pii]
AID - 10.1016/j.curtheres.2007.06.002 [doi]
PST - ppublish
SO  - Curr Ther Res Clin Exp. 2007 May;68(3):127-36. doi: 
      10.1016/j.curtheres.2007.06.002.